Literature DB >> 19304437

Killing of Escherichia coli by beta-lactams at different inocula.

Vincent H Tam1, Kimberly R Ledesma, Kai-Tai Chang, Tsai-Ying Wang, John P Quinn.   

Abstract

Escherichia coli is a common pathogen implicated in intra-abdominal infections; a heavy bacterial burden is often encountered, and the clinical utility of beta-lactams may be limited by the inoculum effect. We examined the impact of a high inoculum on the bactericidal activity of various beta-lactams against E. coli. Two wild-type, an extended-spectrum beta-lactamase-producing, and a plasmid-mediated AmpC-producing strains, were used. Clinically achievable concentrations of piperacillin/tazobactam, ceftriaxone, and ertapenem were investigated. Viable bacterial burden was serially determined for 24 h by quantitative culture. All 3 beta-lactams demonstrated significant killing against the standard inoculum (10(5) CFU/mL) of susceptible strains. However, the activity of piperacillin/tazobactam was drastically reduced with 10(8) CFU/mL of bacteria. Ertapenem was the least affected by the inoculum effect in all strains. Our results suggest that different beta-lactam subclasses have a distinct killing profile against a dense E. coli population. Comparative in vivo/clinical investigations are warranted to validate our findings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19304437     DOI: 10.1016/j.diagmicrobio.2009.01.018

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  10 in total

1.  Mathematical modeling to characterize the inoculum effect.

Authors:  Pratik Bhagunde; Kai-Tai Chang; Renu Singh; Vandana Singh; Kevin W Garey; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

2.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

3.  Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.

Authors:  F Docobo-Pérez; L López-Cerero; R López-Rojas; P Egea; J Domínguez-Herrera; J Rodríguez-Baño; A Pascual; J Pachón
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

4.  In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes.

Authors:  Chunna Guo; Xiaoping Liao; Mingru Wang; Feng Wang; Chaoqun Yan; Xia Xiao; Jiang Sun; Yahong Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

5.  Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem.

Authors:  A Mizrahi; L Chat; M Danjean; C Mory; J C Nguyen Van; G Péan de Ponfilly; F Caméléna; A Le Monnier; B Bercot; A Birgy; H Jacquier; B Pilmis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-03-23       Impact factor: 3.267

6.  Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.

Authors:  Patrick N A Harris; Anton Y Peleg; Jon Iredell; Paul R Ingram; Spiros Miyakis; Andrew J Stewardson; Benjamin A Rogers; Emma S McBryde; Jason A Roberts; Jeff Lipman; Eugene Athan; Sanjoy K Paul; Peter Baker; Tiffany Harris-Brown; David L Paterson
Journal:  Trials       Date:  2015-01-27       Impact factor: 2.279

7.  Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).

Authors:  Roni Bitterman; Fidi Koppel; Cristina Mussini; Yuval Geffen; Michal Chowers; Galia Rahav; Lior Nesher; Ronen Ben-Ami; Adi Turjeman; Maayan Huberman Samuel; Matthew P Cheng; Todd C Lee; Leonard Leibovici; Dafna Yahav; Mical Paul
Journal:  BMJ Open       Date:  2021-02-08       Impact factor: 2.692

8.  Mathematical modeling of the 'inoculum effect': six applicable models and the MIC advancement point concept.

Authors:  Jessica R Salas; Majid Jaberi-Douraki; Xuesong Wen; Victoriya V Volkova
Journal:  FEMS Microbiol Lett       Date:  2020-03-01       Impact factor: 2.742

9.  Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations.

Authors:  Tiffany R Keepers; Marcela Gomez; Donald Biek; Ian Critchley; Kevin M Krause
Journal:  Int Sch Res Notices       Date:  2015-05-19

10.  In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates.

Authors:  Moonsuk Bae; Taeeun Kim; Joung Ha Park; Seongman Bae; Heungsup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Yong Pil Chong
Journal:  Antibiotics (Basel)       Date:  2021-12-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.